The Hippo pathway was initially identified and named through screenings for mutant tumour suppressors in flies, in which loss-of-function mutations of components of the Hippo pathway revealed robust overgrowth as a result of increased cell proliferation and decreased cell death 1 . The observation that this pathway -and its role in cell proliferation -is conserved in mammals spurred great anticipation and has sustained immense interest in recent years as experimental evidence has shown that the Hippo pathway is strongly involved in several processes of cancer progression and, in general, has important regulatory functions in organ development, regeneration and stem cell biology [2] [3] [4] . The central components of this pathway comprise a regulatory serine-threonine kinase module and a transcriptional module. The kinase module includes the mammalian orthologues of Drosophila melanogaster Hippo, mammalian STE20-like protein kinase 1 (MST1; also known as STK4) and MST2 (also known as STK3), and in addition, the large tumour suppressor 1 (LATS1) and LATS2 (REF. 1) (FIG. 1) . YAP and TAZ function as transcriptional co-activators that shuttle between the cytoplasm and the nucleus, where they induce expression of cell-proliferative and anti-apoptotic genes via interactions with transcription factors, particularly TEA domain family members (TEAD) 3 . When the inhibitory Hippo kinase module is 'on' , LATS1 and LATS2 phosphorylate and inactivate YAP and TAZ, and the output gene production is therefore turned off. By contrast, when the kinase module is 'off ' , hypophosphorylated YAP and TAZ translocate into the nucleus and induce target gene expression 4 . In this classic view, the components of the kinase module are tumour suppressors and those of the transcriptional module are oncogenes.
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The observation that this pathway -and its role in cell proliferation -is conserved in mammals spurred great anticipation and has sustained immense interest in recent years as experimental evidence has shown that the Hippo pathway is strongly involved in several processes of cancer progression and, in general, has important regulatory functions in organ development, regeneration and stem cell biology [2] [3] [4] . The central components of this pathway comprise a regulatory serine-threonine kinase module and a transcriptional module. The kinase module includes the mammalian orthologues of Drosophila melanogaster Hippo, mammalian STE20-like protein kinase 1 (MST1; also known as STK4) and MST2 (also known as STK3), and in addition, the large tumour suppressor 1 (LATS1) and LATS2 (REF. 1) (FIG. 1) . The transcriptional module includes yesassociated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ; also known as WWTR1), which are two closely related paralogues that largely mediate the downstream effects of Hippo signalling 1 . YAP and TAZ predominantly show functional redundancy; genetic evidence in mice clearly shows their redundant roles in development 5 and regeneration 6 , as the dual depletion of YAP and TAZ generally results in a more severe phenotype than either single mutation 7 . YAP and TAZ function as transcriptional co-activators that shuttle between the cytoplasm and the nucleus, where they induce expression of cell-proliferative and anti-apoptotic genes via interactions with transcription factors, particularly TEA domain family members (TEAD) 3 . When the inhibitory Hippo kinase module is 'on' , LATS1 and LATS2 phosphorylate and inactivate YAP and TAZ, and the output gene production is therefore turned off. By contrast, when the kinase module is 'off ' , hypophosphorylated YAP and TAZ translocate into the nucleus and induce target gene expression 4 . In this classic view, the components of the kinase module are tumour suppressors and those of the transcriptional module are oncogenes.
In recent years, the complexity of YAP and TAZ regulation has expanded considerably, with the identification of more regulatory components and with evidence showing that the Hippo pathway is interlinked with other cancer-relevant pathways, especially G protein-coupled receptors (GPCRs), and the transforming growth factor-β (TGFβ) and WNT pathways. This highlights that the field is moving away from the idea of a simple linear pathway to a view in which YAP and TAZ are an integral part and a nexus of a network composed of multiple signalling pathways.
In this Progress article, we summarize the latest findings regarding the expanding roles of YAP and TAZ in cancer, discuss the different ways in which the regulation of these proteins is disrupted and describe their potential as therapeutic targets.
Regulation of and by YAP and TAZ
Regulation through the microenvironment. YAP and TAZ are regulated by soluble extracellular factors, cell-cell adhesions and mechanotransduction 3 . Therefore, this pathway is capable of sensing and responding to the physical organization of cells, coordinating these physical signals with chemical cues and ultimately functioning as an integrator and a nexus for both dynamic short-term and long-term regulation of cellular signalling.
Tumour cells generate niches that are different to those found in non-neoplastic tissues. YAP and TAZ regulate these niches by modulating cell-cell and cell-matrix interactions 8 and the production of secretory proteins, such as amphiregulin (AREG; an epidermal growth factor (EGF) family member) 9 , cysteine-rich angiogenic inducer 61 (CYR61) and connective tissue growth factor (CTGF) 3, 10 . In addition, YAP and TAZ are also directly regulated by the extracellular matrix (ECM) 8, 11, 12 , which is itself stiffened in tumours, partly as a result of enhanced integrin signalling 13 . Cells grown on high ECM stiffness show high nuclear localization and subsequent transcriptional activity of YAP and TAZ, whereas in cells that are grown on low stiffness substrates, YAP and TAZ translocate to the cytoplasm and are inactivated 11, 12, 14 . This regulation requires RHO GTPase activity and tension of the actomyosin cytoskeleton but is apparently independent of the Hippo-LATS cascade 8, 12 ; however, other reports have shown that mechanotransduction also includes regulation of YAP and TAZ phosphorylation by LATS kinases 15, 16 . How actin regulates YAP and TAZ is thus unclear but the small GTPase RHO functions as a prime regulator of this actin dependency 12, 15, 17 (FIG. 2b) . Interestingly, recent studies revealed that AMOT is phosphorylated by LATS kinases, which potentiates its inhibitory effects on YAP and TAZ activity 19 . LATS kinases thereby inhibit YAP and TAZ nuclear activity by two different means.
The relationship between YAP and TAZ activity and the ECM provides a feedforward mechanism in which cancer cells drive extracellular stiffening that further activates YAP and TAZ, and these transcriptional co-activators are therefore not only responders but also direct mediators of mechanical signals 8, 14 .
Regulation via extracellular signalling. The Hippo pathway does not seem to have a unique extracellular ligand that exclusively regulates this pathway. Instead, a general role of GPCRs as potent regulators of Hippo signalling has recently been revealed 17 . GPCRs function as key transducers of extracellular signals to the interior of the cell by using hetero trimeric G proteins that consist of α-, β-and γ-subunits 20 . Among the Gα proteins, Gα 11 , Gα 12 , Gα 13 , Gα i , Gα o and Gα q can activate YAP and TAZ, whereas Gα s -coupled signals repress them 17 . These regulatory effects are mediated by LATS kinases; when a GPCR activates RHO GTPase, it subsequently induces F-actin formation to inhibit LATS kinase activity in a MST-independent manner 17 (FIG. 2b) .
In addition to GPCRs, the cytokine receptor leukaemia inhibitory factor receptor (LIFR) can also activate the Hippo kinase module 21 , as can epidermal growth factor (EGF), which dissociates the Hippo kinase complex thereby activating YAP and TAZ 22 . Furthermore, other signalling pathways -such as WNT [23] [24] [25] [26] [27] , TGFβ 10, 28, 29 and bone morphogenetic protein (BMP) 29 -also potentiate YAP and TAZ activity 30 . WNT stimulation diverts YAP and TAZ away from the β-catenin destruction complex, causing β-catenin stabilization as well as YAP and TAZ nuclear accumulation 23 . TAZ interacts with TGFβ-regulated SMAD2 and SMAD3 controlling their nuclear localization and driving transcription 28 . YAP can also engage with SMAD1 and synergize the transcriptional activity downstream of BMP signalling 29 .
Regulation of microRNA biogenesis. MicroRNA (miRNA) suppression has been proposed to promote tumorigenesis 31 . The processing and biogenesis of mi RNAs require stepwise cleavage of long primary miRNA transcripts (pri-miRNA) by the microprocessor and DICER complexes to generate mature mi RNAs that repress expression of target mRNAs. Recent data suggest that YAP induces widespread miRNA repression by modulating the microprocessor complex machinery in a cell density-dependent but apparently TEAD-independent manner 32 ( FIG. 2) . At low cell density, YAP is localized in the nucleus 33 , where it represses miRNA biogenesis by binding and sequestering DEAD box helicase 17 (DDX17) from other members of the microprocessor complex 32 . At high cell density, the Hippo pathwaymediated cytoplasmic retention of YAP allows DDX17 to associate with the microprocessor complex, resulting in enhanced miRNA biogenesis. Furthermore, in YAPinduced mouse models of squamous cell and hepatic carcinoma, the levels of several mi RNAs were decreased, whereas levels of pri-mi RNAs were increased 32 , which suggests an important role of miRNA biogenesis in YAP-induced tumorigenesis. Intriguingly, Chaulk et al. 34 reported that nuclear YAP and TAZ induce the activity of the DICER complex, therefore suggesting that nuclear YAP and TAZ can mediate the processing of specific pre-mi RNAs to mature mi RNAs in some instances 34 . Therefore, in some contexts, YAP and TAZ have opposite roles in miRNA biogenesis. The biological regulation and the mechanisms for these differing phenomena are currently not well understood 32, 34 .
Oncogenic roles of YAP and TAZ in cancer
Hyperactivation of YAP and TAZ is widespread in cancers 2, 4 , and reports of gene amplification and epigenetic modulation of The core inhibitory kinase module is composed of two groups of kinases, the mammalian STE20-like protein kinase 1 (MST1) and MST2, and the large tumour suppressor 1 (LATS1) and LATS2, in combination with their activating adaptor proteins, salvador family WW domain-containing protein 1 (SAV1), MOB kinase activator 1A (MOB1A) and MOB1B. The transcriptional module is composed of the transcriptional co-activators yes-associated protein (YAP) and its paralogue, transcriptional co-activator with PDZ-binding motif (TAZ), and the TEA domain family members (TEAD1-TEAD4). When the upstream kinase module is activated, LATS1 and LATS2 phosphorylate YAP and TAZ, which leads to inhibition of the transcriptional activity through 14-3-3-mediated cytoplasmic retention of YAP and TAZ priming them for ubiquitin-mediated proteasomal degradation 1, 3 . Neurofibromin 2 (NF2) is an additional and potent activator of LATS1 and LATS2 (indicated by the dashed arrow) but is devoid of kinase activity. A yet unidentified kinase (or several of them) may directly phosphorylate LATS1 and LATS2 on the key activation site(s) in a MST1-and MST2-independent manner (indicated by the dashed arrow); when this site is not phosphorylated, the Hippo-LATS pathway is 'off'. When YAP and TAZ are not phosphorylated by LATS kinases, they translocate to the nucleus and bind to sequence specific transcription factors TEAD1-TEAD4 (and other transcription factors, such as SMAD, RUNX, TP73, TBX5 and PAX), which enables the transcription of target genes encoding proteins that are involved in cell proliferation and survival 1, 3 . AMOTL2, angiomotin-like protein 2; AREG, amphiregulin; BIRC5, baculoviral IAP repeat-containing protein 5; CTGF, connective tissue growth factor; CYR61, cysteine-rich angiogenic inducer 61; TF, transcription factor. the YAP and TAZ loci in cancer are similarly prevalent, which implies that YAP-and TAZ-mediated transcriptional activity is important for the development and sustainability of neoplasia 2, 4 . Importantly, studies have revealed that the correlation between YAP and TAZ amplification and transcriptional activity is functionally relevant. Inactivation of the transcriptional module (FIG. 1) in a variety of cancer models -including cell lines, xenografts, transgenic mouse models and flies -reverts principal cancer features such as cancer stem cell properties 3, [35] [36] [37] [38] , epithelialmesenchymal transition (EMT) 36 , increased migration 39 and resistance to anoikis 15 (apoptosis induced by insufficient attachment of cells to a substrate) and increased potential for metastasis 39 . Furthermore, induced expression of YAP and TAZ can trigger transition of normal epithelial cells into metastatic cells via EMT 21, 35, 36, 39 and can confer stem cell characteristics 35, 38 . Interestingly dedifferentiation of adult hepatocytes into progenitor cells was reported upon transient inducible YAP expression 38 . In addition, TAZ, but not YAP, was shown to promote lineage switching from luminal to basal mammary epithelial cells 37 and to confer cancer stem cell features to breast cancer cells 36 . These results highlight not only the potential of YAP and TAZ as effectors in stem cell biology but also the differences in regulation between YAP and TAZ depending on the tissue type. Intriguingly, separate YAP and TAZ ablation in the mouse kidney yields distinct phenotypes; YAP loss leads to the development of dysplastic kidneys, whereas depletion of TAZ results in cystic kidneys 40 . Importantly, additional ablation of TAZ shows no exacerbation of the glomeruli phenotype in YAP-mutant kidneys, indicating their distinct roles during nephrogenesis 40 . Although YAP and TAZ predominantly show functional redundancy 7 , this divergence adds an extra level of complexity and a conceivable level of dynamic regulation to the Hippo pathway in different tissues, but how this interplay and distinct regulation happens is currently not well understood.
Oncogenic activation of YAP and TAZ Given the fact that the Hippo pathway is a prime regulator of cancer pathology, a major conundrum in the field has been the lack of germline or somatic mutations identified in components of the pathway in neoplastic tissues, except for neurofibromin 2 (NF2; also known as Merlin) in neurofibromatosis and malignant mesothelioma, and LATS2 in malignant mesothelioma 2, 4 . NF2 activates the core inhibitory Hippo kinase module under normal circumstances (FIG. 1) and loss of NF2 therefore causes hyperactivation of YAP and TAZ 41 . Importantly, predisposition for neoplasia by NF2 loss is mediated by the activation of YAP, as genetic and pharmacological inhibition of YAP prevents the neoplastic phenotype in Nf2-mutant mice 41, 42 .
KRAS mutations. Activating mutations in
KRAS frequently occur in diverse human carcinomas and are particularly prominent in those of the pancreas, lung and colon. Recent data revealed that YAP is essential for the neoplastic progression of pancreatic ductal adenocarcinoma (PDAC) in Krasmutant mice 43 . In addition, YAP is required for tumour recurrence in the absence of KRAS in Kras-driven murine models of both PDAC 44 and lung cancer 45 , implying the need for combinatorial YAP inhibition in some tumours that are treated with drugs targeting KRAS signalling pathways. However, these observations in pancreatic and lung cancer are in contrast to the results obtained in the liver, in which YAP loss failed to prevent oncogenic Kras-induced hepatocellular carcinoma 41 . Therefore, there are tissue-specific differences in the function of YAP during KRAS-driven tumorigenesis.
Liver kinase B1 mutations. Liver kinase B1 (LKB1; also known as STK11) was originally identified as the tumour suppressor responsible for the inherited cancer disorder Peutz-Jeghers syndrome (PJS) 46 . LKB1 is also mutated in 15-35% of non-small-cell lung carcinomas and 20% of cervical carcinomas 46 . A small interfering RNA (siRNA) screening of the human kinome linked LKB1 to the Hippo-YAP pathway by showing that LKB1 signals through its substrates of the microtubule affinity-regulating kinase (MARK) family to regulate the localization of protein scribble homologue (SCRIB), which can facilitate the activation of the core kinases MST and LATS 47 , which in turn phosphorylate and inactivate YAP (FIG. 2a) . Furthermore, YAP was shown to be functionally essential for the growth of the LKB1-deficient lung adenocarcinoma line A549 and for the liver overgrowth phenotype of the Lkb1-mutant mouse 47 . The tumour suppressor function of LKB1 has primarily been linked to its ability to regulate the AMP-activated protein kinase (AMPK)-mammalian target of rapac mycin (mTOR) pathway. mTOR clearly has an important role downstream of LKB1, as mTOR inhibition by rapamycin efficiently decreases the tumour burden of existing large polyps and reduces the onset of polyposis in an Lkb1
+/− mouse model of PJS 46 . It is noteworthy that YAP can also activate mTOR by inducing miR-29 to inhibit the translation of phosphatase and tensin homologue (PTEN), which is an upstream negative regulator of mTOR 48 (FIG. 2a) . This link between YAP and the LKB1 tumour suppressor pathway has substantial implications for the treatment of LKB1-mutant cancers.
Gα q and Gα 11 mutations.
Deep sequencing studies revealed a high rate of mutations in GPCRs and G proteins across a wide range of human cancers 20 . Strikingly, somatic mutations in GNAQ or GNA11 (which encode Gα q and Gα 11 , respectively) have been observed in more than 80% of uveal melanomas 20 , which is the most common intraocular tumour in adults and accounts for ~5% of all melanomas.
Recently, two independent studies have revealed that cancer-associated Gα q and Gα 11 mutants activate YAP, mediating the oncogenic activity of mutant Gα q and Gα 11 in uveal melanoma development 49, 50 (FIG. 2b) .
On the one hand, Yu et al. 50 showed that cancer-associated Gα q and Gα 11 mutants inhibit LATS, resulting in dephosphorylation and activation of YAP; on the other hand, Feng et al. 49 showed that Gα q stimulated the triple functional domain protein (TRIO)-RHO and TRIO-RAC signalling to promote actin polymerization, which causes the dissociation of AMOT-YAP complexes, thereby contributing to YAP nuclear translocation independently of LATS. Although the mechanisms linking the actin cytoskeleton to YAP activation are poorly understood, both groups showed that YAP is essential in transducing the oncogenic activity of mutant Gα q and Gα 11 to induce uveal melanoma. In addition, both groups successfully used the YAP and TAZ inhibitor verteporfin 42 to block tumour growth of uveal melanoma cells containing Gα q and Gα 11 mutations, suggesting that YAP could be a therapeutic target in these tumours.
Adenomatous polyposis coli mutations and WNT signalling. Adenomatous polyposis coli (APC) is the most commonly mutated tumour suppressor in human colorectal cancers and is best known as a downstream component of the WNT signalling pathway. Several studies in recent years have revealed crosstalk between the WNT and Hippo pathways 30 . YAP and TAZ can interact and cooperate with β-catenin in the nucleus to promote the transcriptional activation of a panel of target genes, such as SOX2, SNAI2, BCL2L1 (which encodes BCL-2-like protein 1) and BIRC5 (which encodes baculoviral IAP repeat-containing protein 5) 25, 26 . Azzolin et al. 23 also revealed that YAP and TAZ are transcriptionally inactivated as a result of sequestration in the β-catenin destruction complex that includes APC, whereas WNT stimulation or loss of APC causes their nuclear localization and activation of YAP-TEADand TAZ-TEAD-dependent transcription (FIG. 2c) . The role of YAP and TAZ as mediators of WNT signalling is further evidenced by an animal model that showed that both YAP and TAZ are required for loss of APC-induced crypt hyperplasia 23 . Moreover, these findings are clinically relevant as YAP and TAZ have been revealed to be independent predictors of colorectal cancer progression 51 . NF2 inhibition 53 . Whether this activation of YAP and TAZ is a general feature of oncogenic viruses awaits further studies.
Virus

YAP as a tumour suppressor
Although YAP behaves as an oncogene in several cancers, recent data suggest an interesting hypothesis that YAP also has tumour suppressor functions in certain contexts.
Suppressing WNT signalling. Although YAP and TAZ mediate the WNT signalling response, other studies suggest that cytoplasmic YAP and TAZ can dampen WNT signalling by multiple mechanisms 30 . YAP and TAZ recruit β-transducin repeat-containing protein (βTRCP) to the β-catenin destruction complex to degrade β-catenin in the absence of WNT 23 (FIG. 3a) . Cytoplasmic YAP and TAZ also suppress WNT signalling by sequestering β-catenin in the cytoplasm 54 . As Dishevelled (DVL) facilitates the WNT signalling transcriptional response when forming a complex with β-catenin-T cell factor (TCF), cytoplasmic YAP and TAZ also suppress WNT signalling by sequestering DVL in the cytoplasm 24, 27 . Barry et al. 24 found that loss of YAP can lead to WNT hypersensitivity with subsequent stem cell expansion and hyperplasia during mouse intestinal regeneration, whereas transgenic overexpression of YAP restricts WNT signals. Furthermore, YAP is silenced in a subset of highly aggressive and undifferentiated human colorectal cancers, and its re-expression can restrict the growth of colorectal carcinoma xenografts, suggesting a potential tumour suppressor role for YAP in this tissue 24 . Thus, a plausible scenario is one in which only cytoplasmic YAP and TAZ function as inhibitors of β-catenin, whereas nuclear YAP and TAZ function as positive mediators of WNT-associated intestinal transformation 23 .
Triggering DNA damage-induced apoptosis.
In normal haematological cells, oncogeneinduced DNA damage promotes ataxia telangiectasia mutated (ATM) activation and subsequent activation of the JUN N-terminal kinase (JNK) to phosphorylate the adaptor protein 14-3-3, which releases ABL1 tyrosine kinase from the cytoplasm into the nucleus 55, 56 (FIG. 3b) . ABL1 then phosphorylates YAP on a tyrosine residue and forms a complex with the tumour suppressor TP73 (also known as p73) to support the trans cription of pro-apoptotic genes, such as BAX (which encodes BCL-2-associated X gene) and PIG3 (also known as TP53I3) 55 . Cottini et al. 56 identified that YAP was consistently upregulated in tumour cell lines of epithelial origin but was markedly downregulated in haematological malignancies, including lymphomas, leukaemias and multiple myeloma. Low expression of YAP prevents ABL1-induced apoptosis in the presence of DNA damage in these haematological malignancies 56 . Re-expression of YAP in multiple myeloma cells with YAP deletion or knockdown of MST1 in multiple myeloma cells with wild-type YAP, promoted apoptosis and growth arrest 56 . These results suggest that YAP has a tumour suppressor function whereas the Hippo kinase module has an oncogenic function in combination with ABL1 in the context of DNA damage in haematological malignancies. Of note, in contrast to YAP, focal deletions affecting the TAZ locus were not detected in multiple myeloma, suggesting that haematological cancers preferentially inactivate YAP 56 . Interestingly, a recurrent inactivating mutation encoding a G17V substitution in the GTP-binding domain of RHOA GTPase was observed in T cell lymphoma 57 . This mutation functions in a dominant-negative manner and thereby inhibits RHOA function 57 . Given the importance of RHO in YAP activation (FIG. 2) , it is possible that the RHOA mutation could inactivate YAP and thus inhibit YAP-TP73-mediated apoptosis in T cell lymphoma, although this awaits formal examination.
A possible explanation for the conflicting cancer-related functions of YAP is that it can form complexes with various transcription factors that have distinct functions, which might be differentially altered in distinct types of cancers. YAP may induce the expression of pro-apoptotic genes by binding to TP73 in haematological cancers 56 . More speculatively, YAP and TAZ may differentially contribute to tumorigenesis by binding to various partners, depending on the cellular context. This flexibility adds an extra level of complexity to the regulation of cancer by YAP and TAZ in different tissues. YAP recruits β-transducin repeat-containing protein (βTRCP) to the destruction complex for β-catenin degradation, which leads to β-catenin downregulation in the absence of WNT 23 . Cytoplasmic YAP also restricts the nuclear translocation of β-catenin 54 and Dishevelled (DVL) 24, 27 , which facilitates the WNT transcriptional response when forming a complex with β-catenin-T cell factor (TCF). Expression of YAP abrogates the DVL-mediated upregulation of the WNT target genes, such as LGR5 (which encodes leucine-rich repeat-containing G-protein coupled receptor 5) and AXIN2 (REFS 23, 24) . b | Oncogene-induced DNA damage promotes the activation of the ataxia telangiectasia mutated (ATM)-JUN N-terminal kinase (JNK) axis to phosphorylate the adaptor protein 14-3-3 at the binding site of ABL1, releasing the ABL1 tyrosine kinase from the cytoplasm into the nucleus where it phosphorylates YAP on a tyrosine residue 55 . Tyrosine-phosphorylated YAP then forms a complex with the tumour suppressor TP73 to support the transcription of pro-apoptotic genes, such as BAX (which encodes BCL-2-associated X gene) and PUMA (which encodes p53-upregulated modulator of apoptosis; also known as BBC3) 56 . Mammalian STE20-like protein kinase 1 (MST1)-induced activation of the Hippo pathway suppresses this pro-apoptotic response by phosphorylating YAP at specific serine residues and thereby inhibiting its activity 56 . APC, adenomatous polyposis coli; GSK3, glycogen synthase kinase 3; LATS, large tumour suppressor.
YAP and TAZ as therapeutic targets The studies described above provide evidence for the therapeutic benefits of YAP and TAZ inhibition in cancer. The best targets for small-molecule therapeutics are generally kinases. However, efforts in this direction are frustrated by the fact that the majority of kinases in the Hippo pathway are mainly tumour suppressors, which has led to a hunt for therapeutic options beyond the core Hippo kinases.
Verteporfin. Verteporfin, which is a clinical photosensitizer in photocoagulation therapy for macular degeneration, was identified via a small-molecule library screen as a compound that inhibits the transcriptional activity of YAP 42 . Verteporfin abrogates the interaction between YAP and TEAD, and thus inhibits YAP-induced transcription (FIG. 2d) . Importantly, in addition to the above-mentioned effects on uveal melanoma cells 49, 50 , verteporfin also blocks YAP-induced liver tumorigenesis 42 , demonstrating the therapeutic potential of disrupting the YAP-TEAD and TAZ-TEAD interactions in treating cancers with aberrant YAP and TAZ hyperactivation.
VGLL4-mimicking peptide. Recent data suggest that vestigial-like family member 4 (VGLL4) is a natural inhibitor of the YAP-TEAD interaction and is capable of preventing YAP-induced cell proliferation and tumorigenesis in both D. melanogaster and mouse models 58 (FIG. 2d) . Jiao et al. 59 identified that VGLL4 was potentially downregulated in human gastric cancer and established an association between upregulation of YAP target genes and poor prognosis of gastric cancer. On the basis of the structure of the VGLL4-TEAD4 complex, Jiao et al. 59 developed a peptide-based YAP inhibitor mimicking this function of VGLL4. Treatment with this peptide suppresses tumour growth of human primary gastric cancer grown in nude mice, as well as tumorigenesis in the Helicobacter pylori-infected mouse model of gastric cancer 59 , providing an opportunity for treating this malignancy. As most peptide-based drugs are expensive to manufacture and inefficient to administer orally -as a result of their rapid degradation by internal enzymes -further manipulations of this peptide might be needed to extend such a therapeutic strategy.
Statins. Sorrentino et al.
60 screened 640 clinically used compounds for their ability to sequester YAP and TAZ in the cytoplasm and found that statins, a class of drugs used to lower cholesterol levels in patients with hypercholesterolaemia, had the most potent effect. Statins mechanistically inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductasewhich is the rate-limiting enzyme of the mevalonate cholesterol biosynthesis pathway -reducing geranylgeranyl pyrophosphate, which is required for membrane localization and activation of RHO GTPases. The mevalonate-RHO axis thus promotes nuclear accumulation of YAP and TAZ 60, 61 ( FIG. 2d) . Inhibition of the mevalonate pathway had antiproliferative and apoptotic effects in breast cancer cells and prevented the transcriptional co-activator Yorkie (the fly homologue of YAP and TAZ) from inducing eye overgrowth in D. melanogaster 60 . Also of note, substantial evidence in animal models of a wide range of cancers -including breast, colon, pancreas and liver cancers -indicates that statins have tumour suppressor effects, a conclusion that is supported by accumulating clinical studies showing a considerable negative association of statins with cancer occurrence or survival 62 .
Conclusions and perspectives
Given the frequent perturbation of Hippo pathway activity in human cancers, the general lack of somatic or germline mutations in core members of the pathway is still puzzling 2, 4 . One possibility is that the pathway is fundamental during development, when constitutive activation of YAP and TAZ could be lethal. An additional plausible scenario is that mutations in components of the Hippo pathway might be identified in rare types of cancers, as the recent finding of LATS2 loss-of-function mutations in malignant mesothelioma-derived cell lines implies 4 . In addition, it is clear that some of the proteins that are implicated in regulation of the Hippo pathway are 'derailed' and mutated in cancers, such as the junctional protein E-cadherin (in breast adenocarcinomas) 63 , the LIM domain-containing protein AJUBA (in head and neck squamous carcinoma) 63 , LKB1 (REFS 46, 47, 64) , RHOA 57 , and GPCRs and their cognate G proteins 17, 20, 49, 50 . YAP has very recently been shown to function not only as a proto-oncogene but also as a tumour suppressor depending on the cellular context 24, 56 , revealing apparent cell context-dependent properties of this pathway. This dual role is not surprising given recent results that have identified new regulators and functions of the Hippo-YAP and Hippo-TAZ pathway, and have provided evidence for a model in which network-level pathway perturbations affect the activity of YAP and TAZ to contribute to tumorigenesis. Several recent proteomic studies examining the Hippo pathway interactome 65 have implicated a large number of proteins and pathways that may be linked to YAP and TAZ and, thus, when further scrutinized, may contribute to our understanding of the composition and structure of this network. Delineating these interactions will have important clinical implications.
